Pfizer Steams Ahead Despite Price Cuts; Merck Ramps Up In China: Emerging Markets Earnings Round Up (Part 3)
This article was originally published in PharmAsia News
You may also be interested in...
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..
After announcing the intent to form a partnership a year ago, Merck & Co. announced Sept. 13, a collaboration with BGI (formerly the Beijing Genomics Institute) for discovery and development of biomarkers and genomic technologies
NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership